by myNEO Tx Admin | Sep 5, 2024 | News
🌟 We are excited to announce that Lien will be speaking at an event organized by Ontmoeting en Ontspanning Kanker titled “Personalized Immunotherapy: A Revolution in Cancer Care.” 🌟The talk (in Dutch) is dedicated to helping cancer patients, their...by Wim Mees | Sep 3, 2024 | News, Event List
myNEO Therapeutics will attend job fairs and participate in the following events: Bio Europe –Stockholm, Sweden – November 04 – November 06, 2024 World Vaccine Congress Europe – Oral presentation – Barcelona, Spain– October 28 – October 31, 2024...by myNEO Tx Admin | May 30, 2024 | Article, News
Following neoantigen discovery and validation, mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epitope mRNA constructs to optimize translation efficiency and target-specific immunogenicity while avoiding...by myNEO Tx Admin | Mar 8, 2024 | News
Today, on #internationalwomensday , we’re proud to celebrate the remarkable women of myNEO Therapeutics. Their talent, dedication, and leadership are at the heart of our success. Thank you for your invaluable contributions! #womeninhealthcareby myNEO Tx Admin | Feb 15, 2024 | News
Last week, our team came together for an engaging and informative training session about the cloud-based version of our neoantigen discovery ImmunoEngine led by Lore Van Oudenhove and Steve Lefever. These training sessions demonstrate our dedication to continuous...by myNEO Tx Admin | Nov 16, 2023 | Article, News
myNEO Therapeutics has been quite active in recent months, taking part in various conference presentations and participating in panel discussions about neoantigen discovery. Additionally, we’re pleased to announce that our CEO, Cedric, received the Medical...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).